ACC.20 with the World Congress of Cardiology 2020
Polygenic risk scores, LDL and SBP in lifetime risk assessment
News from the ACC.20/WCC Scientific Sessions Virtual meeting Integration of a polygenic risk score (PGS) with LDL cholesterol and systolic blood pressure (SBP), major cardiovascular risk factors,1 offers the potential to personalize cardiovascular disease prevention and target early intervention to those who need it most,…
read more »
ODYSSEY HoFH: Alirocumab a potential adjunctive therapeutic option
News from the ACC.20/WCC Scientific Sessions Virtual meeting Treatment with the PCSK9 monoclonal antibody alirocumab reduced LDL cholesterol by 35.6% on top of maximally tolerated lipid lowering therapy, in patients with homozygous familial hypercholesterolaemia (HoFH), the rare and severe form of this inherited high cholesterol…
read more »
More inclisiran data
News from the ACC.20/WCC Scientific Sessions Virtual meeting Pooled analysis including more than 2700 patient years of exposure showed that twice-yearly inclisiran reduced LDL cholesterol by at least 50% and was well tolerated. Inclisiran is a novel small interfering RNA that specifically inhibits PCSK9 production…
read more »
ANGPTL3 monoclonal antibody evinacumab promising in homozygous familial hypercholesterolaemia
News from the ACC.20/WCC Scientific Sessions Virtual meeting Results of this latebreaker indicate therapeutic potential for evinacumab, a fully human monoclonal antibody inhibitor of angiopoietin-like 3 protein (ANGPTL3), in patients with homozygous familial hypercholesterolaemia, the most severe form of this inherited high cholesterol disorder. All…
read more »
